Top

Published in:

Open Access 01-07-2018 | Original Article

Nonmetastatic pancreatic cancer

Improved survival with chemoradiotherapy > 40 Gy after systemic treatment

Authors: Sebastian Bachmayer, M.D., Gerd Fastner, M.D., Andrea Vaszi, M.D., Wolfgang Iglseder, M.D., Peter Kopp, Ph.D., Josef Holzinger, M.D., Adam Dinnewitzer, M.D., Gabriel Rinnerthaler, M.D., Simon Peter Gampenrieder, M.D., Klaus Emmanuel, M.D., Richard Greil, M.D., Felix Sedlmayer, M.D., Franz Zehentmayr, M.D., M.Sc.

Published in: Strahlentherapie und Onkologie | Issue 7/2018

Abstract

Purpose

The role of radiotherapy (RT) for nonmetastatic pancreatic cancer is still a matter of debate since randomized control trials have shown inconsistent results. The current retrospective single-institution study includes both resected and unresected patients with nonmetastasized pancreatic cancer. The aim is to analyze overall survival (OS) after irradiation combined with induction chemotherapy.

Patients and methods

Of the 73 patients with nonmetastatic pancreatic cancer eligible for the present analysis, 42 (58%) patients had adjuvant chemoradiotherapy (CRT), while 31 (42%) received CRT as primary treatment. In all, 65 (89%) had chemotherapy at any time before, during, or after RT, and 39 (53%) received concomitant CRT. The median total dose was 50 Gy (range 12–77 Gy), while 61 (84%) patients received >40 Gy.

Results

With a median follow-up of 22 months (range 1.2–179.8 months), 14 (19%) are still alive and 59 (81%) of the patients have died, whereby 51 (70%) were cancer-related deaths. Median OS and the 2‑year survival rate were 22.9 months (1.2–179.8 months) and 44%, respectively. In addition, 61 (84%) patients treated with >40 Gy had a survival advantage (median OS 23.7 vs. 17.3 months, p = 0.026), as had patients with 4 months minimum of systemic treatment (median OS 27.5 vs. 14.3 months, p = 0.0004).

Conclusion

CRT with total doses >40 Gy after induction chemotherapy leads to improved OS in patients with nonmetastatic pancreatic cancer.

Available only for authorised users

Malvezzi M, Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C, Negri E (2017) European cancer mortality predictions for the year 2017, with focus on lung cancer. Ann Oncol 28(5):1117–1123. https://doi.org/10.1093/annonc/mdx033 CrossRefPubMed

American Cancer Society (2016) Cancer facts & figures 2016. American Cancer Society, Atlanta

Khorana AA, Mangu PB, Berlin J, Engebretson A, Hong TS, Maitra A, Mohile SG, Mumber M, Schulick R, Shapiro M, Urba S, Zeh HJ, Katz MHG (2017) Potentially curable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35(20):2324. https://doi.org/10.1200/Jco.2017.72.4948 CrossRefPubMed

Silvestris N, Brunetti O, Vasile E, Cellini F, Cataldo I, Pusceddu V, Cattaneo M, Partelli S, Scartozzi M, Aprile G, Casadei Gardini A, Morganti AG, Valentini V, Scarpa A, Falconi M, Calabrese A, Lorusso V, Reni M, Cascinu S (2017) Multimodal treatment of resectable pancreatic ductal adenocarcinoma. Crit Rev Oncol Hematol 111:152–165. https://doi.org/10.1016/j.critrevonc.2017.01.015 CrossRefPubMed

Seufferlein T, Porzner M, Becker T, Budach V, Ceyhan G, Esposito I, Fietkau R, Follmann M, Friess H, Galle P, Geissler M, Glanemann M, Gress T, Heinemann V, Hohenberger W, Hopt U, Izbicki J, Klar E, Kleeff J, Kopp I, Kullmann F, Langer T, Langrehr J, Lerch MM, Lohr M, Luttges J, Lutz M, Mayerle J, Michl P, Moller P, Molls M, Munter M, Nothacker M, Oettle H, Post S, Reinacher-Schick A, Rocken C, Roeb E, Saeger H, Schmid R, Schmiegel W, Schoenberg M, Siveke J, Stuschke M, Tannapfel A, Uhl W, Unverzagt S, van Oorschot B, Vashist Y, Werner J, Yekebas E (2013) S3-guideline exocrine pancreatic cancer. Z Gastroenterol 51(12):1395–1440. https://doi.org/10.1055/s-0033-1356220 CrossRefPubMed

Kalser MH, Ellenberg SS (1985) Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120(8):899–903CrossRefPubMed

Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Buchler MW (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350(12):1200–1210. https://doi.org/10.1056/NEJMoa032295 CrossRefPubMed

Van Laethem JL, Hammel P, Mornex F, Azria D, Van Tienhoven G, Vergauwe P, Peeters M, Polus M, Praet M, Mauer M, Collette L, Budach V, Lutz M, Van Cutsem E, Haustermans K (2010) Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol 28(29):4450–4456. https://doi.org/10.1200/JCO.2010.30.3446 CrossRefPubMedPubMedCentral

Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouche O, Bosset JF, Aparicio T, Mineur L, Azzedine A, Hammel P, Butel J, Stremsdoerfer N, Maingon P, Bedenne L (2008) Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5‑FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study. Ann Oncol 19(9):1592–1599. https://doi.org/10.1093/annonc/mdn281 CrossRefPubMed

10.

Loehrer PJ Sr., Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, Flynn P, Ramanathan RK, Crane CH, Alberts SR, Benson AB 3rd (2011) Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 29(31):4105–4112. https://doi.org/10.1200/JCO.2011.34.8904 CrossRefPubMedPubMedCentral

11.

Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, Borbath I, Bouche O, Shannon J, Andre T, Mineur L, Chibaudel B, Bonnetain F, Louvet C (2016) Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without Erlotinib: the LAP07 randomized clinical trial. JAMA 315(17):1844–1853. https://doi.org/10.1001/jama.2016.4324 CrossRefPubMed

12.

Huguet F, Andre T, Hammel P, Artru P, Balosso J, Selle F, Deniaud-Alexandre E, Ruszniewski P, Touboul E, Labianca R, de Gramont A, Louvet C (2007) Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 25(3):326–331. https://doi.org/10.1200/JCO.2006.07.5663 CrossRefPubMed

13.

Verbeke CS, Menon KV (2009) Redefining resection margin status in pancreatic cancer. HPB (Oxford) 11(4):282–289. https://doi.org/10.1111/j.1477-2574.2009.00055.x CrossRef

14.

Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A (2006) Redefining the R1 resection in pancreatic cancer. Br J Surg 93(10):1232–1237. https://doi.org/10.1002/bjs.5397 CrossRefPubMed

15.

Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21(1):109–122CrossRefPubMed

16.

Hall EJ, Giaccia A (2006) Time, dose, and fractionation in radiotherapy. In: Hall EJ (ed) Radiobiology for the radiologist, 6th edn. Lippincott Williams & Wilkins, Philadelphia, pp 378–398

17.

Joiner MC, Bentzen SM (2009) Fractionation: the linear-quadratic approach. In: Joiner MC (ed) Basic clinical radiobiology, 4th edn. Edward Arnold, London, pp 102–120CrossRef

18.

Unkel S, Belka C, Lauber K (2016) On the analysis of clonogenic survival data: statistical alternatives to the linear-quadratic model. Radiat Oncol 11:11. https://doi.org/10.1186/s13014-016-0584-z CrossRefPubMedPubMedCentral

19.

Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, de Wit LT, Hennipman A, Wils J (1999) Adjuvant radiotherapy and 5‑fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230(6):776–782 (discussion 782–774)CrossRefPubMedPubMedCentral

20.

Herman JM, Swartz MJ, Hsu CC, Winter J, Pawlik TM, Sugar E, Robinson R, Laheru DA, Jaffee E, Hruban RH, Campbell KA, Wolfgang CL, Asrari F, Donehower R, Hidalgo M, Diaz LA Jr., Yeo C, Cameron JL, Schulick RD, Abrams R (2008) Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol 26(21):3503–3510. https://doi.org/10.1200/JCO.2007.15.8469 CrossRefPubMedPubMedCentral

21.

Corsini MM, Miller RC, Haddock MG, Donohue JH, Farnell MB, Nagorney DM, Jatoi A, McWilliams RR, Kim GP, Bhatia S, Iott MJ, Gunderson LL (2008) Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975–2005). J Clin Oncol 26(21):3511–3516. https://doi.org/10.1200/JCO.2007.15.8782 CrossRefPubMed

22.

Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH, Lillemoe KD (2000) Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4(6):567–579CrossRefPubMed

23.

Morganti AG, Falconi M, van Stiphout RG, Mattiucci GC, Alfieri S, Calvo FA, Dubois JB, Fastner G, Herman JM, Maidment BW 3rd, Miller RC, Regine WF, Reni M, Sharma NK, Ippolito E, Valentini V (2014) Multi-institutional pooled analysis on adjuvant chemoradiation in pancreatic cancer. Int J Radiat Oncol Biol Phys 90(4):911–917. https://doi.org/10.1016/j.ijrobp.2014.07.024 CrossRefPubMed

24.

Hall WA, Colbert LE, Liu Y, Gillespie T, Lipscomb J, Hardy C, Kooby DA, Prabhu RS, Kauh J, Landry JC (2013) The influence of adjuvant radiotherapy dose on overall survival in patients with resected pancreatic adenocarcinoma. Cancer 119(12):2350–2357. https://doi.org/10.1002/cncr.28047 CrossRefPubMedPubMedCentral

25.

Kooby DA, Gillespie TW, Liu Y, Byrd-Sellers J, Landry J, Bian J, Lipscomb J (2013) Impact of adjuvant radiotherapy on survival after pancreatic cancer resection: an appraisal of data from the national cancer data base. Ann Surg Oncol 20(11):3634–3642. https://doi.org/10.1245/s10434-013-3047-x CrossRefPubMedPubMedCentral

26.

Lim YJ, Kim K, Chie EK, Kim B, Ha SW (2015) Role of adjuvant radiotherapy in left-sided pancreatic cancer-population-based analysis with propensity score matching. J Gastrointest Surg 19(12):2183–2191. https://doi.org/10.1007/s11605-015-2941-x CrossRefPubMed

27.

Mellon EA, Springett GM, Hoffe SE, Hodul P, Malafa MP, Meredith KL, Fulp WJ, Zhao X, Shridhar R (2014) Adjuvant radiotherapy and lymph node dissection in pancreatic cancer treated with surgery and chemotherapy. Cancer 120(8):1171–1177. https://doi.org/10.1002/cncr.28543 CrossRefPubMed

28.

Rutter CE, Park HS, Corso CD, Lester-Coll NH, Mancini BR, Yeboa DN, Johung KL (2015) Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: an analysis of the National Cancer Data Base. Cancer 121(23):4141–4149. https://doi.org/10.1002/cncr.29652 CrossRefPubMed

29.

Sugawara A, Kunieda E (2014) Effect of adjuvant radiotherapy on survival in resected pancreatic cancer: a propensity score surveillance, epidemiology, and end results database analysis. J Surg Oncol 110(8):960–966. https://doi.org/10.1002/jso.23752 CrossRefPubMed

30.

Xia Z, Jia X, Chen K, Li D, Xie J, Xu H, Mao Y (2016) Survival benefits from postoperative radiation therapy on lymph node positive patients with pancreatic adenocarcinoma. Oncotarget 7(29):46646–46652. https://doi.org/10.18632/oncotarget.9620 PubMedPubMedCentralCrossRef

31.

Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297(3):267–277. https://doi.org/10.1001/jama.297.3.267 CrossRefPubMed

32.

Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Olah A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Buchler MW, European Study Group for Pancreatic C (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled tria. JAMA 304(10):1073–1081. https://doi.org/10.1001/jama.2010.1275 CrossRefPubMed

33.

Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, Faluyi O, O’Reilly DA, Cunningham D, Wadsley J, Darby S, Meyer T, Gillmore R, Anthoney A, Lind P, Glimelius B, Falk S, Izbicki JR, Middleton GW, Cummins S, Ross PJ, Wasan H, McDonald A, Crosby T, Ma YT, Patel K, Sherriff D, Soomal R, Borg D, Sothi S, Hammel P, Hackert T, Jackson R, Buchler MW, European Study Group for Pancreatic C (2017) Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 389(10073):1011–1024. https://doi.org/10.1016/S0140-6736(16)32409-6 CrossRefPubMed

34.

Sinn M, Bahra M, Liersch T, Gellert K, Messmann H, Bechstein W, Waldschmidt D, Jacobasch L, Wilhelm M, Rau BM, Grutzmann R, Weinmann A, Maschmeyer G, Pelzer U, Stieler JM, Striefler JK, Ghadimi M, Bischoff S, Dorken B, Oettle H, Riess H (2017) CONKO-005: adjuvant chemotherapy with Gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: a Multicenter randomized phase III trial. J Clin Oncol 35(29):3330–3337. https://doi.org/10.1200/JCO.2017.72.6463 CrossRefPubMed

35.

Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T, Ohashi Y, Group JS (2016) Adjuvant chemotherapy of S‑1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 388(10041):248–257. https://doi.org/10.1016/S0140-6736(16)30583-9 CrossRefPubMed

36.

Valle JW, Palmer D, Jackson R, Cox T, Neoptolemos JP, Ghaneh P, Rawcliffe CL, Bassi C, Stocken DD, Cunningham D, O’Reilly D, Goldstein D, Robinson BA, Karapetis C, Scarfe A, Lacaine F, Sand J, Izbicki JR, Mayerle J, Dervenis C, Olah A, Butturini G, Lind PA, Middleton MR, Anthoney A, Sumpter K, Carter R, Buchler MW (2014) Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol 32(6):504–512. https://doi.org/10.1200/JCO.2013.50.7657 CrossRefPubMed

37.

Stocken DD, Buchler MW, Dervenis C, Bassi C, Jeekel H, Klinkenbijl JH, Bakkevold KE, Takada T, Amano H, Neoptolemos JP (2005) Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 92(8):1372–1381. https://doi.org/10.1038/sj.bjc.6602513 CrossRefPubMedPubMedCentral

38.

Butturini G, Stocken DD, Wente MN, Jeekel H, Klinkenbijl JH, Bakkevold KE, Takada T, Amano H, Dervenis C, Bassi C, Buchler MW, Neoptolemos JP (2008) Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg 143(1):75–83. https://doi.org/10.1001/archsurg.2007.17 (discussion 83)CrossRefPubMed

39.

Ren F, Xu YC, Wang HX, Tang L, Ma Y (2012) Adjuvant chemotherapy, with or without postoperative radiotherapy, for resectable advanced pancreatic adenocarcinoma: continue or stop? Pancreatology 12(2):162–169. https://doi.org/10.1016/j.pan.2012.02.002 CrossRefPubMed

40.

Liao WC, Chien KL, Lin YL, Wu MS, Lin JT, Wang HP, Tu YK (2013) Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis. Lancet Oncol 14(11):1095–1103. https://doi.org/10.1016/S1470-2045(13)70388-7 CrossRefPubMed

41.

Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG (1985) Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5‑fluorouracil alone with radiation plus concurrent and maintenance 5‑fluorouracil—an Eastern Cooperative Oncology Group study. J Clin Oncol 3(3):373–378. https://doi.org/10.1200/JCO.1985.3.3.373 CrossRefPubMed

42.

Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S, Wasan H, Crosby T, Jephcott C, Roy R, Radhakrishna G, McDonald A, Ray R, Joseph G, Staffurth J, Abrams RA, Griffiths G, Maughan T (2013) Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol 14(4):317–326. https://doi.org/10.1016/S1470-2045(13)70021-4 CrossRefPubMedPubMedCentral

43.

Wilson JM, Fokas E, Dutton SJ, Patel N, Hawkins MA, Eccles C, Chu KY, Durrant L, Abraham AG, Partridge M, Woodward M, O’Neill E, Maughan T, McKenna WG, Mukherjee S, Brunner TB (2016) ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer. Radiother Oncol 119(2):306–311. https://doi.org/10.1016/j.radonc.2016.03.021 CrossRefPubMedPubMedCentral

44.

Brunner T, Fokas E (2016) The results of the LAP07 trial should not be misunderstood as the end of chemoradiotherapy in pancreatic cancer. Strahlenther Onkol 192(12):956–958. https://doi.org/10.1007/s00066-016-1058-9 CrossRefPubMed

45.

Moureau-Zabotto L, Phelip JM, Afchain P, Mineur L, Andre T, Vendrely V, Lledo G, Dupuis O, Huguet F, Touboul E, Balosso J, Louvet C (2008) Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en Oncologie phase II study. J Clin Oncol 26(7):1080–1085. https://doi.org/10.1200/JCO.2007.12.8223 CrossRefPubMed

46.

Louvet C, Andre T, Lledo G, Hammel P, Bleiberg H, Bouleuc C, Gamelin E, Flesch M, Cvitkovic E, de Gramont A (2002) Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 20(6):1512–1518. https://doi.org/10.1200/JCO.2002.20.6.1512 CrossRefPubMed

Title: Nonmetastatic pancreatic cancer
Improved survival with chemoradiotherapy > 40 Gy after systemic treatment
Authors: Sebastian Bachmayer, M.D.
Gerd Fastner, M.D.
Andrea Vaszi, M.D.
Wolfgang Iglseder, M.D.
Peter Kopp, Ph.D.
Josef Holzinger, M.D.
Adam Dinnewitzer, M.D.
Gabriel Rinnerthaler, M.D.
Simon Peter Gampenrieder, M.D.
Klaus Emmanuel, M.D.
Richard Greil, M.D.
Felix Sedlmayer, M.D.
Franz Zehentmayr, M.D., M.Sc.
Publication date: 01-07-2018
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 7/2018
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-018-1281-7

ACC 2024 Congress

Springer Medicine

Nonmetastatic pancreatic cancer

Improved survival with chemoradiotherapy > 40 Gy after systemic treatment

Abstract

Purpose

Patients and methods

Results

Conclusion

ACC 2024 Congress

Springer Medicine

Abstract

Purpose

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2018

Intensity-modulated radiotherapy of prostate cancer with simultaneous integrated boost after molecular imaging with 18F-choline-PET/CT

Verlängerung des rezidivfreien und Gesamtüberlebens beim Ovarialkarzinom im Stadium III durch hypertherme intraperitoneale Chemotherapie (HIPEC)

Abschätzung von Langzeitrisiken der modernen Strahlentherapie bei Patientinnen mit Mammakarzinom: Evidenz zu Strahlendosen an Lunge und Herz

Cancer patients’ wish for psychological support during outpatient radiation therapy

The impact of [68Ga]PSMA I&T PET/CT on radiotherapy planning in patients with prostate cancer

Systemic administration of heparin ameliorates radiation-induced oral mucositis—preclinical studies in mice